{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:07Z","timestamp":1787239927307,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Ningxia","award":["No: 2024AAC02080"],"award-info":[{"award-number":["No: 2024AAC02080"]}]},{"name":"the Natural Science Foundation of Ningxia","award":["No: 2024AAC02080"],"award-info":[{"award-number":["No: 2024AAC02080"]}]},{"name":"the Natural Science Foundation of Ningxia","award":["No: 2024AAC02080"],"award-info":[{"award-number":["No: 2024AAC02080"]}]},{"name":"the Natural Science Foundation of Ningxia","award":["No: 2024AAC02080"],"award-info":[{"award-number":["No: 2024AAC02080"]}]},{"name":"the Natural Science Foundation of Ningxia","award":["No: 2024AAC02080"],"award-info":[{"award-number":["No: 2024AAC02080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02291-y","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:06:24Z","timestamp":1777118784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification and validation of an intratumor heterogeneity-related prognostic signature in triple-negative breast cancer: a study based on integrative machine learning and single-cell sequencing"],"prefix":"10.1186","volume":"28","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaobang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"14","key":"2291_CR1","doi-asserted-by":"publisher","first-page":"15704","DOI":"10.1002\/cam4.6176","volume":"12","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Tao LF, Liu JY, Wang YX, Huang H, Jiang YN, et al. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy. Cancer Med. 2023;12(14):15704\u201319.","journal-title":"Cancer Med"},{"issue":"1","key":"2291_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2291_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"SY Wu","year":"2022","unstructured":"Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer. 2022;21(1):84.","journal-title":"Mol Cancer"},{"issue":"7","key":"2291_CR4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750\u201367.","journal-title":"J Clin Invest"},{"issue":"7","key":"2291_CR5","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688\u201398.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2291_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428\u201340. e5.","journal-title":"Cancer Cell"},{"issue":"9","key":"2291_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.20892\/j.issn.2095-3941.2024.0222","volume":"21","author":"R Shan","year":"2024","unstructured":"Shan R, Dai LJ, Shao ZM, Jiang YZ. Evolving molecular subtyping of breast cancer advances precision treatment. Cancer Biol Med. 2024;21(9):731\u20139.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"2291_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25(5):353\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2291_CR9","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021;184(8):2239\u2013e5439.","journal-title":"Cell"},{"issue":"9","key":"2291_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53(9):1334\u201347.","journal-title":"Nat Genet"},{"issue":"1","key":"2291_CR11","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232.","journal-title":"Nat Commun"},{"issue":"7","key":"2291_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21(7):751\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"2291_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12967-022-03355-1","volume":"20","author":"D Song","year":"2022","unstructured":"Song D, Wang X. DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls. J Transl Med. 2022;20(1):150.","journal-title":"J Transl Med"},{"issue":"1","key":"2291_CR14","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1038\/s41467-018-06052-0","volume":"9","author":"M Karaayvaz","year":"2018","unstructured":"Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018;9(1):3588.","journal-title":"Nat Commun"},{"key":"2291_CR15","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"1","key":"2291_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21.","journal-title":"Genome Med"},{"issue":"6","key":"2291_CR17","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","journal-title":"Brief Bioinform"},{"key":"2291_CR18","doi-asserted-by":"publisher","first-page":"731023","DOI":"10.1155\/2013\/731023","volume":"2013","author":"R Gunthner","year":"2013","unstructured":"Gunthner R, Anders HJ. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm. 2013;2013:731023.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"2291_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/ni.2304","volume":"13","author":"H Xu","year":"2012","unstructured":"Xu H, Zhu J, Smith S, Foldi J, Zhao B, Chung AY, et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol. 2012;13(7):642\u201350.","journal-title":"Nat Immunol"},{"issue":"11","key":"2291_CR20","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","volume":"55","author":"BG Nixon","year":"2022","unstructured":"Nixon BG, Kuo F, Ji L, Liu M, Capistrano K, Do M, et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity. 2022;55(11):2044\u2013e585.","journal-title":"Immunity"},{"issue":"1","key":"2291_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13058-021-01427-6","volume":"23","author":"G Gatti","year":"2021","unstructured":"Gatti G, Betts C, Rocha D, Nicola M, Grupe V, Ditada C, et al. Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. Breast Cancer Res. 2021;23(1):48.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2291_CR22","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129(4):1785\u2013800.","journal-title":"J Clin Invest"},{"issue":"16","key":"2291_CR23","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1007\/s00432-023-05274-0","volume":"149","author":"J Xiao","year":"2023","unstructured":"Xiao J, Huang F, Li L, Zhang L, Xie L, Liu B. Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets. J Cancer Res Clin Oncol. 2023;149(16):15003\u201311.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2291_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/cas.16433","volume":"116","author":"K Nakamura","year":"2025","unstructured":"Nakamura K, Saito K, Higashi C, Kozuka Y, Yuasa H, Nishimura Y, et al. Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis. Cancer Sci. 2025;116(3):744\u201352.","journal-title":"Cancer Sci"},{"issue":"1","key":"2291_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s10020-025-01079-8","volume":"31","author":"W Zhu","year":"2025","unstructured":"Zhu W, Yi Q, Chen Z, Wang J, Zhong K, Ouyang X, et al. Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy. Mol Med. 2025;31(1):43.","journal-title":"Mol Med"},{"issue":"4","key":"2291_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/cells14040272","volume":"14","author":"M Gurrea-Rubio","year":"2025","unstructured":"Gurrea-Rubio M, Fox DA, Castresana JS. CD6 in human disease. Cells. 2025;14(4):272.","journal-title":"Cells"},{"issue":"5","key":"2291_CR27","doi-asserted-by":"publisher","first-page":"e145662","DOI":"10.1172\/jci.insight.145662","volume":"6","author":"JH Ruth","year":"2021","unstructured":"Ruth JH, Gurrea-Rubio M, Athukorala KS, Rasmussen SM, Weber DP, Randon PM, et al. CD6 is a target for cancer immunotherapy. JCI Insight. 2021;6(5):e145662.","journal-title":"JCI Insight"},{"issue":"2","key":"2291_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00262-023-03578-1","volume":"73","author":"M Gurrea-Rubio","year":"2024","unstructured":"Gurrea-Rubio M, Wu Q, Amin MA, Tsou PS, Campbell PL, Amarista CI, et al. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells. Cancer Immunol Immunother. 2024;73(2):34.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2291_CR29","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41416-024-02617-7","volume":"130","author":"HH Eum","year":"2024","unstructured":"Eum HH, Jeong D, Kim N, Jo A, Na M, Kang H, et al. Single-cell RNA sequencing reveals myeloid and T cell co-stimulation mediated by IL-7 anti-cancer immunotherapy. Br J Cancer. 2024;130(8):1388\u2013401.","journal-title":"Br J Cancer"},{"issue":"1","key":"2291_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1189\/jlb.0313122","volume":"95","author":"AM Crawley","year":"2014","unstructured":"Crawley AM, Vranjkovic A, Faller E, McGuinty M, Busca A, Burke SC, et al. Jak\/STAT and PI3K signaling pathways have both common and distinct roles in IL-7-mediated activities in human CD8\u2009+\u2009T cells. J Leukoc Biol. 2014;95(1):117\u201327.","journal-title":"J Leukoc Biol"},{"issue":"30","key":"2291_CR31","doi-asserted-by":"publisher","first-page":"e2304319120","DOI":"10.1073\/pnas.2304319120","volume":"120","author":"G Micevic","year":"2023","unstructured":"Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, et al. IL-7R licenses a population of epigenetically poised memory CD8(+) T cells with superior antitumor efficacy that are critical for melanoma memory. Proc Natl Acad Sci U S A. 2023;120(30):e2304319120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2291_CR32","doi-asserted-by":"publisher","first-page":"986447","DOI":"10.3389\/fimmu.2022.986447","volume":"13","author":"Q Guo","year":"2022","unstructured":"Guo Q, Wu CY, Jiang N, Tong S, Wan JH, Xiao XY, et al. Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma. Front Immunol. 2022;13:986447.","journal-title":"Front Immunol"},{"key":"2291_CR33","first-page":"5259187","volume":"2022","author":"H Qiao","year":"2022","unstructured":"Qiao H, Lv R, Pang Y, Yao Z, Zhou X, Zhu W, et al. Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer. Anal Cell Pathol (Amst). 2022;2022:5259187.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"37","key":"2291_CR34","doi-asserted-by":"publisher","first-page":"10304","DOI":"10.1073\/pnas.1608069113","volume":"113","author":"H Xiao","year":"2016","unstructured":"Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc Natl Acad Sci U S A. 2016;113(37):10304\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2291_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nri.2018.3","volume":"18","author":"E RodrIguez","year":"2018","unstructured":"RodrIguez E, Schetters STT, van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat Rev Immunol. 2018;18(3):204\u201311.","journal-title":"Nat Rev Immunol"},{"key":"2291_CR36","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"2291_CR37","doi-asserted-by":"publisher","first-page":"12105","DOI":"10.1038\/ncomms12105","volume":"7","author":"Y Gao","year":"2016","unstructured":"Gao Y, Mutter-Rottmayer E, Greenwalt AM, Goldfarb D, Yan F, Yang Y, et al. A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis. Nat Commun. 2016;7:12105.","journal-title":"Nat Commun"},{"issue":"8","key":"2291_CR38","doi-asserted-by":"publisher","first-page":"e1006842","DOI":"10.1371\/journal.pgen.1006842","volume":"13","author":"K Yamanaka","year":"2017","unstructured":"Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? PLoS Genet. 2017;13(8):e1006842.","journal-title":"PLoS Genet"},{"issue":"2","key":"2291_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41568-019-0222-9","volume":"20","author":"F Mitchell","year":"2020","unstructured":"Mitchell F, Ashani TWJNRC. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89\u2013106.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2291_CR40","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/ijc.31258","volume":"142","author":"MJ Esther","year":"2018","unstructured":"Esther MJ, Lisa MH, Amanda IP, Jocelyn K, Teri AL, Sue AI et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study. Int J Cancer. 2018;142(11):2273\u201385.","journal-title":"Int J Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02291-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02291-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:25:26Z","timestamp":1781738726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02291-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02291-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The human-related studies were cleared by the Ethics Committee of the General Hospital of Ningxia Medical University (KYLL-2025-1243). These studies adhered to local laws and institutional guidelines. Informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}